XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.4
Consolidated Statements of Equity - USD ($)
$ in Thousands
Total
Adoption of accounting standard
Total Caladrius Biosciences, Inc. Stockholders' Equity
Total Caladrius Biosciences, Inc. Stockholders' Equity
Adoption of accounting standard
Series B Convertible Preferred Stock
Common Stock
Additional Paid in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Accumulated Deficit
Adoption of accounting standard
Treasury Stock
Non- Controlling Interest in Subsidiary
Beginning Balance (in shares) at Dec. 31, 2018         10,000 9,866,000            
Beginning Balance at Dec. 31, 2018 $ 37,454 $ (62) $ 37,726 $ (62) $ 0 $ 10 $ 436,433 $ (32) $ (397,977) $ (62) $ (708) $ (272)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (19,352)   (19,361)           (19,361)     9
Unrealized gain (loss) on marketable securities 34   34         34        
Share-based compensation (in shares)           94,000            
Share-based compensation 1,165   1,165     $ 0 1,165          
Net proceeds from issuance of common stock (in shares)           569,000            
Net proceeds from issuance of common stock and warrants 1,314   1,314     $ 1 1,313          
Ending Balance (in shares) at Dec. 31, 2019         10,000 10,529,000            
Ending Balance at Dec. 31, 2019 20,553   20,816   $ 0 $ 11 438,911 2 (417,400)   (708) (263)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (8,141)   (8,150)           (8,150)     9
Unrealized gain (loss) on marketable securities (15)   (15)         (15)        
Share-based compensation (in shares)           53,000            
Share-based compensation 1,117   1,117     $ 0 1,117          
Net proceeds from issuance of common stock (in shares)           8,807,000            
Net proceeds from issuance of common stock and warrants 18,728   18,728     $ 8 18,720          
Ending Balance (in shares) at Dec. 31, 2020         10,000 19,389,000            
Ending Balance at Dec. 31, 2020 $ 32,242   $ 32,496   $ 0 $ 19 $ 458,748 $ (13) $ (425,550)   $ (708) $ (254)